ClinicalTrials.gg
CompletedNCT00305422Updated Jun 11, 2009

Effect of Quetiapine on Negative Symptoms and Cognition

A Phase 3 interventional study of Quetiapine fumarate and Risperidone in Schizophrenia, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-06-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing quetiapine in Schizophrenia — none open to participants now, none under way, none of them phase 3. quetiapine · Schizophrenia.

Enrollment
51st of 67
45 · median 100
Started
2001
with 2 others
Phase 3
25 of 70
none open now
Registered
27th of 70
by date
Lead sponsor
26 of 70
AstraZeneca

Among the 70 studies testing quetiapine in Schizophrenia, this one is the 51st largest by enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2001, is one of 25 in phase 3, and was the 27th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 70 studies testing quetiapine in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About quetiapine

quetiapine: first FDA approval 1997 (SEROQUEL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 70 studies testing quetiapine in Schizophrenia as a file.
02

Study summary

The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • men and women aged 18 to 65 years with diagnosis of schizophrenia
  • score of at least 4 CGI, PANSS negative subscale score > 21
  • fulfil the criterion to be right-handed for inclusion in the fMRI investigations

Exclusion criteria

Exclusion Criteria:

  • Substance or alcohol dependence
  • female patients who are pregnant, lactating or at risk of pregnancy
  • history of organic CNS-trauma, epilepsy, meningoencephalitis, psychosurgery, instable somatic conditions
  • risk of suicide or aggressive behaviour
  • history of electroconvulsive therapy, Parkinson's disease, Prolactin-dependent tumor

For the subset of subjects for the fMRI investigations the following additional exclusion criteria is valid as:

  • existence of metal in the body as by cardiac pacemaker, coil, total prosthesis, metal splinter, metal articulation, metal balls.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
45 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12

Secondary outcomes

  1. Change from baseline in PANSS negative symptom total score, PANSS subscores, CGI, CGI-severity of illness, HAMD, Simpson-Angus-Scale, BPRS, specific PANSS items , Startle reflex.

07

Study locations

1 site
  • Research Site
    Munich, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001 and a completion of Jan 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2006
First posted
Mar 22, 2006
Start
Nov 2001
CompletionActual
Jan 2003
Last update
Jun 11, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00305422
Lead sponsor
AstraZeneca
First posted
Mar 22, 2006
Start date
Nov 2001
Completion
Jan 2003
Last update
Jun 11, 2009

Study contacts

AstraZeneca Germany Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quetiapine · Risperidone

Start the discussion